Nab-paclitaxel does not extend survival in biliary tract cancer; though has benefits for some скачать в хорошем качестве

Nab-paclitaxel does not extend survival in biliary tract cancer; though has benefits for some

#gastrointestinalneoplasms #clinicaltrials #cancerpatients #cancerresearch Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma. These results are from the phase 3 S1815 trial conducted by the SWOG Cancer Research Network. 3SWOG S1815 was designed as a randomized phase 3 trial to compare this nab-paclitaxel combination to the standard gemcitabine–cisplatin regimen to determine whether it would extend survival times in a larger group of patients newly diagnosed with advanced BTCs. Get the latest medical and health news at medicaldialogues.in Follow us on Twitter:   / medicaldialogs   Facebook:   / medicaldialogues   Instagram:   / medicaldialogues   LinkedIn:   / medical-dialogues   Website: https://medicaldialogues.in/